Valuation: Relay Therapeutics, Inc.

Market Cap 4.18B 3.62B 3.42B 3.1B 5.81B 400B 5.85B 40.79B 15.72B 203B 15.69B 15.34B 646B P/E 2026 *
-11.9x
P/E 2027 * -11.8x
Enterprise Value 3.61B 3.12B 2.95B 2.68B 5.02B 346B 5.05B 35.22B 13.57B 175B 13.54B 13.25B 557B EV / Sales 2026 *
342x
EV / Sales 2027 * 226x
Free-Float
91.39%
Yield 2026 *
-
Yield 2027 * -
1 day+1.01%
1 week+0.11%
Current month+3.70%
1 month-4.03%
3 months+28.70%
6 months+83.98%
Current year+125.30%
1 week 18.1
Extreme 18.1
19.43
1 month 17.96
Extreme 17.96
21.27
Current year 7.01
Extreme 7.01
21.27
1 year 4.05
Extreme 4.05
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Sell

Chief Financial Officer

-17,717 0.0081%
08/09/26 Sell

Chief Executive Officer

-48,199 0.0220%
08/09/26 Sell

Chief Technology Officer

-8,530 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+1.01%+0.11%+377.69%+98.34% 4.14B
+0.56%-5.82%-2.45%+9.99% 45.48B
+0.66%-2.34%+340.62%+530.14% 43.68B
+1.49%-0.78%+41.90%+24.75% 43.09B
+2.11%-1.24%+9.09%+78.25% 39.4B
+0.34%-4.94%+9.34%+40.23% 31.91B
+0.53%-2.08% - - 17.31B
+1.34%+0.70%+21.35%+112.62% 16.4B
+2.07%+0.78%+13.07%+30.91% 14.24B
-1.85%-5.33%+78.63%+31.45% 13.28B
Average +0.83%-2.77%+98.81%+106.30% 26.89B
Weighted average by Cap. +0.94%-3.22%+80.96%+127.79%

Financials

2026 *2027 *
Net sales 10.53M 9.13M 8.61M 7.81M 14.66M 1.01B 14.76M 103M 39.64M 512M 39.56M 38.69M 1.63B 16.56M 14.35M 13.54M 12.28M 23.04M 1.59B 23.21M 162M 62.31M 805M 62.19M 60.82M 2.56B
Net income -320M -278M -262M -238M -446M -30.71B -449M -3.13B -1.21B -15.58B -1.2B -1.18B -49.53B -347M -301M -284M -258M -483M -33.29B -487M -3.39B -1.31B -16.89B -1.3B -1.28B -53.7B
Net Debt -571M -495M -467M -423M -794M -54.7B -800M -5.57B -2.15B -27.75B -2.14B -2.1B -88.22B -442M -383M -361M -328M -615M -42.36B -620M -4.32B -1.66B -21.49B -1.66B -1.62B -68.32B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
14/09/26 $19.06 +1.01% 2,400,234
11/09/26 $18.87 -0.11% 4,164,383
10/09/26 $18.89 +1.23% 3,000,717
09/09/26 $18.66 -2.35% 6,061,328
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
19.06USD
Average target price
27.08USD
Spread / Average Target
+42.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!